HomeNews

News

Adcetris Plus Revlimid and Rituxan Continues to Enhance Relapsed/Refractory Diffuse Giant B-Cell Lymphoma Outcomes

Adcetris Plus Revlimid and Rituxan Continues to Enhance Relapsed/Refractory Diffuse Giant B-Cell Lymphoma OutcomesIncluding Adcetris (brentuximab vedotin) to Revlimid (lenalidomide) and Rituxan (rituximab)...

Sure, You Can Donate Many Unused Most cancers Medicine

I first heard the time period “monetary toxicity” years in the past after I listened to a presentation for oncologists about why sufferers...

First-Line Rybrevant Plus Lazcluze Exhibits Development Towards Total Survival in EGFR-Optimistic NSCLC

First-Line Rybrevant Plus Lazcluze Exhibits Development Towards Total Survival in EGFR-Optimistic NSCLCWithin the first line of therapy, Rybrevant (amivantamab) plus Lazcluze (lazertinib) demonstrated...

Therapy Breakthroughs Arrive for SCLC

Pictures by Jill StifflerFor Sabrina Potts, the approval by the Meals and Drug Administration (FDA) of Imdelltra (tarlatamab-dlle) in Could 2024 for the...

Professionals and Cons of Surgical procedure Approaches in Gynecologic Cancers

From open stomach surgical procedure to laparoscopic surgical procedure, there are numerous surgical approaches to contemplate for sufferers with gynecologic most cancers. For...

Hot Topics